Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02 2023 - 7:00AM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines, today
announced that management will present at the Canaccord Genuity
43rd Annual Growth Conference on Wednesday, August 9, 2023, at 4:30
p.m. ET.
A live webcast of the presentation, which will be conducted in
fireside chat format, will be available on the Investors & News
section of Stoke’s website at
https://investor.stoketherapeutics.com/ and can be accessed by
following this Link. A replay of the webcast will be available for
30 days following the presentation.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines. Using
Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene
Output) approach, Stoke is developing antisense oligonucleotides
(ASOs) to selectively restore protein levels. Stoke’s first
compound, STK-001, is in clinical testing for the treatment of
Dravet syndrome, a severe and progressive genetic epilepsy. Dravet
syndrome is one of many diseases caused by a haploinsufficiency, in
which a loss of ~50% of normal protein levels leads to disease.
Stoke is pursuing the development of STK-002 for the treatment of
autosomal dominant optic atrophy (ADOA), the most common inherited
optic nerve disorder. Stoke’s initial focus is haploinsufficiencies
and diseases of the central nervous system and the eye, although
proof of concept has been demonstrated in other organs, tissues,
and systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/ or follow
Stoke on Twitter at @StokeTx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230802344569/en/
Stoke Investor Contact: Eric Rojas Vice President,
Investor Relations IR@stoketherapeutics.com 617-312-2754
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
From Oct 2024 to Oct 2024
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
From Oct 2023 to Oct 2024